APY-d3
Based on 1 Customer Validation
APY-d3 is a highly selective EphA4 receptor inhibitor, with an IC50 value of 17-56 nM for human EphA4, an IC50 value of 20 nM for mouse EphA4, and a Kd value of 138 nM for EphA4-LBD. APY-d3 binds to EphA4, blocks its interaction with ephrin ligands, inhibits tyrosine phosphorylation of EphA4, prevents growth cone collapse, and does not induce EphA4 phosphorylation in primary cortical neurons. APY-d3 adopts a β-hairpin conformation stabilized by an N-terminal to C-terminal disulfide bond. APY-d3 can be used in research related to amyotrophic lateral sclerosis, Alzheimer's disease, stroke, neurodegenerative diseases and cancer.
For research use only. We do not sell to patients.
- Purity : 99.18%
- Formula: C63H86N16O17S2
- Molecular Weight:1403.58
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
|
EPHA4 17-56 nM (IC50) |
EphA4-LBD 138 nM (Kd) |
In Vitro
APY-d3 (0-72 h) potently inhibits ephrin-A5 binding to mouse and human EphA4 with IC50 values of 20 nM and 17 nM respectively, exhibits a plasma half-life of >72 hours, maintains activity in rat CSF for >72 hours, and is over 100-fold selective for EphA4 over other Eph receptors[1].
APY-d3 binds to the purified EphA4 LBD with an average KD of 27 nM[1].
APY-d3 inhibits ephrin-A5-induced EphA4 tyrosine phosphorylation in transfected HEK293 cells with an IC50 of 0.24 μM[1].
APY-d3 (15-30 μM; 24 h) is non-toxic to HT22 neuronal cells at concentrations up to 30 μM after 24 hours of incubation[1].
APY-d3 (150-200 nM) inhibits EphA4 phosphorylation by 30-40% in ephrin-A5-stimulated HEK293 cells[2].
APY-d3 (150-200 nM) completely inhibits growth cone collapse in retinal explants[2].
APY-d3 (0.1-100 nM; ~1 hour) potently inhibits ephrin-A5 AP binding to immobilized EphA4 Fc with an average IC50 of 20 nM, with modest reductions in potency in the presence of serum albumin[3].
APY-d3 (20-minute pre-incubation; 10-minute stimulation) inhibits ephrin-A5 Fc-induced EphA4 tyrosine phosphorylation in HEK-EphA4 cells with an IC50 of 130 nM[3].
APY-d3 (more than 72 hours) exhibits high protease resistance, with an in vitro plasma half-life of more than 72 hours[3].
APY-d3 (40 μM) binds to purified EphA4-LBD with a Kd of 138 nM as measured by isothermal titration calorimetry[4].
APY-d3 adopts a rigid, folded conformation in solution, as evidenced by increased chemical shift dispersion in its 1D 1H NMR spectrum[4].
APY-d3 induces chemical shift perturbations of Met115 in the GH loop of 13Cε-Met-labeled EphA4-LBD, with minimal effects on Met164 in the JK loop, as measured by 2D [13C, 1H] HSQC NMR spectroscopy[4].
APY-d3 binds to EphA4-LBD in a stabilized β-hairpin conformation, as revealed by X-ray crystallography (PDB ID 5JR2)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT22 neuronal cells
-
Concentration:15 μM; 30 μM
-
Incubation Time:24 h
-
Result:Showed no evidence of cytotoxicity at concentrations 100-fold higher than its IC50 for EphA4 activation inhibition, with viable cell counts comparable to vehicle-treated controls.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, adult, 10-12 weeks old, photothrombotic ischemic stroke induced in forelimb motor cortex)[2]
-
Dosage:5 mM
-
Administration:i.c.v.; 0.25 μl/h; 14 days (starting 48 hours post-stroke)
-
Result:Showed motor performance on accelerating rotarod and horizontal ladder task comparable to inactive peptide-treated mice after 2 weeks of treatment.
Did not enhance functional recovery compared to inactive peptide control, regardless of housing condition.
Demonstrated improved rotarod performance from day 35 post-stroke onward when housed in enriched environment, with no significant difference compared to inactive peptide-treated mice in enriched housing.
Maintained rotarod performance at ~70% of baseline in standard housing, similar to inactive peptide-treated mice in standard housing.
Showed no difference in horizontal ladder task foot fault rates compared to inactive peptide groups at any time point.
Reached mean brain concentrations of 150 nM in contralesional hemisphere and 530 nM in ipsilesional hemisphere at day 13 post-pump implantation, with one ipsilesional sample measuring up to 1200 nM.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1403.58
-
Formula C63H86N16O17S2
-
Color White to off-white
-
Sequence
{β-Ala}-Pro-Tyr-Cys-Val-Tyr-Arg-{β-Ala}-Ser-Trp-Ser-Cys (Disulfide bridge: Cys3-Cys10)
-
Sequence Shortening
{β-Ala}-PYCVYR-{β-Ala}-SWSC (Disulfide bridge: Cys3-Cys10)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (71.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Primary Embryonic Cortical Neuron Culture
Primary embryonic cortical neuron culture isolates cortical tissue from prenatal rodents, dissociates it into single cells, and maintains neurons in vitro so that neurite extension, neuronal marker expression, synapse formation, survival, and treatment responses can be examined outside the intact brain.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (308 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Olson EJ, et al. Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability. ACS medicinal chemistry letters. 2016 Sep 08;7(9):841-6. [Content Brief]
[2]. de Boer A, et al. Environmental enrichment during the chronic phase after experimental stroke promotes functional recovery without synergistic effects of EphA4 targeted therapy. Human molecular genetics. 2020 Mar 13;29(4):605-617. [Content Brief]
[3]. Gomez-Soler M, et al. Lipidation and PEGylation Strategies to Prolong the Half-Life of a Nanomolar EphA4 Receptor Antagonist. European journal of medicinal chemistry. 2023 Dec 15;262:115876. [Content Brief]
[4]. Prentiss AM, et al. Constrained β-Hairpins Targeting the EphA4 Ligand Binding Domain. Journal of medicinal chemistry. 2024 Dec 26;67(24):22245-22253. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7125 mL | 3.5623 mL | 7.1246 mL | 17.8116 mL |
| 5 mM | 0.1425 mL | 0.7125 mL | 1.4249 mL | 3.5623 mL | |
| 10 mM | 0.0712 mL | 0.3562 mL | 0.7125 mL | 1.7812 mL | |
| 15 mM | 0.0475 mL | 0.2375 mL | 0.4750 mL | 1.1874 mL | |
| 20 mM | 0.0356 mL | 0.1781 mL | 0.3562 mL | 0.8906 mL | |
| 25 mM | 0.0285 mL | 0.1425 mL | 0.2850 mL | 0.7125 mL | |
| 30 mM | 0.0237 mL | 0.1187 mL | 0.2375 mL | 0.5937 mL | |
| 40 mM | 0.0178 mL | 0.0891 mL | 0.1781 mL | 0.4453 mL | |
| 50 mM | 0.0142 mL | 0.0712 mL | 0.1425 mL | 0.3562 mL | |
| 60 mM | 0.0119 mL | 0.0594 mL | 0.1187 mL | 0.2969 mL |